Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02081378
Title A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

chronic myeloid leukemia

acute lymphoblastic leukemia

Therapies

Asciminib

Asciminib + Imatinib

Asciminib + Dasatinib

Asciminib + Nilotinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Hematology / Oncology Boston Massachusetts 02215 United States Details
University of Michigan Comprehensive Cancer Center SC Ann Arbor Michigan 48109 United States Details
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering New York New York 10065 United States Details
Oregon Health and Science University SC-6 Portland Oregon 97239 United States Details
University of Texas/MD Anderson Cancer Center UT MD Anderson Houston Texas 77030-4009 United States Details
Huntsman Cancer Institute SC Salt Lake City Utah 84112 United States Details
Novartis Investigative Site Adelaide South Australia 5000 Australia Details
Novartis Investigative Site Paris Cedex 10 Cedex 10 75475 France Details
Novartis Investigative Site Bordeaux 33076 France Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Frankfurt 60590 Germany Details
Novartis Investigative Site Jena 07740 Germany Details
Novartis Investigative Site Roma RM 00161 Italy Details
Novartis Investigative Site Kobe-shi Hyogo 650-0017 Japan Details
Novartis Investigative Site Uijeongbu si Gyeonggi Do 11759 Korea, Republic of Details
Novartis Investigative Site Seoul Seocho Gu 06591 Korea, Republic of Details
Novartis Investigative Site Amsterdam 1081 HV Netherlands Details
Novartis Investigative Site Singapore 169608 Singapore Details
Novartis Investigative Site Madrid 28006 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field